Vertex Pharmaceuticals (VRTX) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with VRTX
Recent news

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
VRTX

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
VRTX

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
VRTX

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
VRTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 39.30
- MACD 12/26/9
- -4.88
- EMA 9 of MACD
- -2.89
- MACD histogram
- -1.99
- SMA 50
- $519.90
- Price below SMA 50
- EMA 50
- $512.86
- Price below EMA 50
- SMA 200
- $474.65
- Price above SMA 200
- EMA 200
- $478.92
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $4.21 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
VRTX

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
VRTX

Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
VRTX

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
VRTX

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
VRTX

2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
VRTX

2 Healthcare Stocks That Just Delivered Great News for Investors
2 Healthcare Stocks That Just Delivered Great News for Investors
VRTX

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
VRTX

Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
VRTX

CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
VRTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Vertex Pharmaceuticals
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Executive Chairman | 1956 |
| Dr. Reshma Kewalramani FASN, M.D. | CEO, President & Director | 1973 |
| Mr. Charles F. Wagner Jr. | Executive VP, COO & CFO | 1968 |
| Mr. Amit K. Sachdev J.D. | Executive VP & Chief Patient and External Affairs Officer | 1968 |
| Dr. Ourania Tatsis Ph.D. | Executive VP & Chief Product Affairs Officer | 1970 |
| Dr. Carmen Bozic M.D. | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | 1963 |
| Dr. Mark Bunnage D.Phil | Executive VP & Chief Scientific Officer | 1969 |
| Ms. Susie Lisa C.F.A. | Senior Vice President of Investor Relations | — |
| Ms. Joy Liu J.D. | EVP, Chief Legal Officer & Corporate Secretary | 1978 |
| Ms. Nina Devlin | Senior VP & Chief Communications Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 39.30
- MACD 12/26/9
- -4.88
- EMA 9 of MACD
- -2.89
- MACD histogram
- -1.99
- SMA 50
- $519.90
- Price below SMA 50
- EMA 50
- $512.86
- Price below EMA 50
- SMA 200
- $474.65
- Price above SMA 200
- EMA 200
- $478.92
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $442.00
- Average
- $576.11
- High
- $665.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.0 | +0.8 | +7.1 | |||||||||
| 2022 | +9.2 | -6.4 | +13.1 | +2.7 | +2.6 | +4.6 | -2.4 | +2.9 | -0.2 | +4.9 | +0.7 | -10.0 |
| 2023 | +13.0 | -8.5 | +8.2 | +7.7 | -6.2 | +8.7 | +1.4 | +0.2 | -1.0 | +4.1 | -3.9 | +15.9 |
| 2024 | +5.5 | -3.0 | -3.4 | -6.6 | +13.2 | -0.3 | +5.2 | -2.0 | -2.2 | +1.3 | -0.6 | -13.5 |
| 2025 | +13.8 | +2.0 | +0.3 | +5.1 | -11.4 | -0.1 | +1.0 | -15.4 | -2.3 | +5.3 | +1.8 | +6.5 |
| 2026 | +3.9 | +5.3 | -8.1 | -4.4 | +5.6 | +13.3 | -4.2 | +15.7 | -4.5 | -0.7 |



